Search Results

You are looking at 201 - 210 of 576 items for :

  • Refine by Access: All x
Clear All
Full access

Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience

Seth A. Wander, Hyo S. Han, Mark L. Zangardi, Andrzej Niemierko, Veronica Mariotti, Leslie S.L. Kim, Jing Xi, Apurva Pandey, Siobhan Dunne, Azadeh Nasrazadani, Avinash Kambadakone, Casey Stein, Maxwell R. Lloyd, Megan Yuen, Laura M. Spring, Dejan Juric, Irene Kuter, Ioannis Sanidas, Beverly Moy, Therese Mulvey, Neelima Vidula, Nicholas J. Dyson, Leif W. Ellisen, Steven Isakoff, Nikhil Wagle, Adam Brufsky, Kevin Kalinsky, Cynthia X. Ma, Joyce O’Shaughnessy, and Aditya Bardia

common toxicities include leukopenia/neutropenia, fatigue, diarrhea (for abemaciclib), and rare instances of QTc prolongation (for ribociclib). 1 Although palbociclib and ribociclib have similar pharmacodynamic and pharmacokinetic properties (with

Full access

Cancer Survivorship: We’ve Only Just Begun

Mary S. McCabe

Survivorship Panel that is developing guidelines for the care of the cancer survivor, focusing initially on recommendations for immunizations, exercise, chronic pain, sleep disturbances, sexual issues, anxiety, depression, fatigue, and cognitive function. Each

Full access

Immunotherapies for Lung Cancer

Matthew A. Gubens

immunotherapy (eg, nausea, fatigue), and when they do occur, are typically less than grade 3. Immunotoxicity, however, is associated with checkpoint inhibitors. Most of the immune-related AEs are due to inflammation of organ systems and end in “-itis.” They are

Full access

New Developments in Thyroid Cancer

Robert I. Haddad

cardiac monitoring is with EKG, not echocardiogram. More commonly, diarrhea, rash, and fatigue are reported. “Be careful with the 300 mg dose of vandetanib, and be prepared to dose-reduce,” Dr. Haddad advised. Anaplastic Thyroid Cancer Anaplastic

Full access

Cancer Pain Management: Strategies for Safe and Effective Opioid Prescribing

Judith A. Paice

quality-of-life issues, such as hormonal changes affecting libido and fertility, decreased bone health, fatigue, and suppression of testosterone. “We think more carefully now when we are embarking on a long-term plan of using opioids,” Dr. Paice revealed

Full access

Cancer Survivorship: We’ve Only Just Begun

Mary S. McCabe

Survivorship Panel that is developing guidelines for the care of the cancer survivor, focusing initially on recommendations for immunizations, exercise, chronic pain, sleep disturbances, sexual issues, anxiety, depression, fatigue, and cognitive function. Each

Full access

Unusual Adverse Events in a Patient With BRAF-Mutated Non–Small Cell Lung Cancer Treated With BRAF/MEK Inhibition

Rohan Maniar, Stephanie M. Gallitano, Sameera Husain, Golnaz Moazami, Michael J. Weiss, and Catherine A. Shu

study (ClinicalTrials.gov identifier: NCT01336634 ). 5 , 6 Common adverse events (AEs) affecting >30% of patients receiving this combination treatment include pyrexia, chills, fatigue, peripheral edema, nausea/vomiting, diarrhea, abdominal pain

Full access

NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023

Featured Updates to the NCCN Guidelines

Edward M. Schaeffer, Sandy Srinivas, Nabil Adra, Yi An, Daniel Barocas, Rhonda Bitting, Alan Bryce, Brian Chapin, Heather H. Cheng, Anthony Victor D’Amico, Neil Desai, Tanya Dorff, James A. Eastham, Thomas A. Farrington, Xin Gao, Shilpa Gupta, Thomas Guzzo, Joseph E. Ippolito, Michael R. Kuettel, Joshua M. Lang, Tamara Lotan, Rana R. McKay, Todd Morgan, George Netto, Julio M. Pow-Sang, Robert Reiter, Mack Roach III, Tyler Robin, Stan Rosenfeld, Ahmad Shabsigh, Daniel Spratt, Benjamin A. Teply, Jonathan Tward, Richard Valicenti, Jessica Karen Wong, Ryan A. Berardi, Dorothy A. Shead, and Deborah A. Freedman-Cass

therapies compared with those receiving only ADT and docetaxel. The populations receiving the triplet and doublet therapies experienced similar rates neutropenia, febrile neutropenia, fatigue, and neuropathy, although grade ≥3 adverse events occurred 63% of

Full access

Stabilization of Metastatic Uterine Leiomyosarcoma Using Pembrolizumab

Katherine Cotangco, Mary Meram, and M. Patrick Lowe

a 90% PD-L1 expression. The assay also confirmed estrogen and progesterone receptor negativity, pTEN positivity, and mismatch repair status stability ( Table 1 ). After cycle 8, the patient began experiencing dyspnea and fatigue. Her CT scans showed

Full access

Novel Agents for Metastatic Triple-Negative Breast Cancer: Finding the Positive in the Negative

Neelima Vidula, Leif W. Ellisen, and Aditya Bardia

). Talazoparib is FDA approved for HER2-negative advanced breast cancer with germline BRCA1/2 mutations. 17 Both olaparib and talazoparib are well tolerated, but toxicity includes myelosuppression, fatigue, and gastrointestinal problems. The BROCADE 3 phase